In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5-[sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay

被引：61

作者：

Ahmed, AOA

van de Sande, WWJ

van Vianen, W

van Belkum, A

Fahal, AH

Verbrugh, HA

Bakker-Woudenberg, IAJM

机构：

[1] Erasmus Univ, Med Ctr, Dept Med Microbiol & Infect Dis, NL-3015 GD Rotterdam, Netherlands

[2] Univ Khartoum, Mycetoma Res Grp, Inst Endemic Dis, Khartoum, Sudan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 07期

关键词：

D O I：

10.1128/AAC.48.7.2742-2746.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Susceptibilities of Madurella mycetomatis against amphotericin B and itraconazole in vitro were determined by protocols based on NCCLS guidelines (visual reading) and a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay for fungal viability. The XTT assay was reproducible and sensitive for both antifungals. Itraconazole (MIC at which 50% of the isolates tested are inhibited [MIC50]) of 0.06 to 0.13 mg/liter) was superior to amphotericin B (MIC50 of 0.5 to 1.0 mg/liter).

引用

页码：2742 / 2746

页数：5

共 27 条

[11] In vitro activities of 10 antifungal drugs against 508 dermatophyte strains
Fernández-Torres, B
Carrillo, AJ
Martín, E
Del Palacio, A
Moore, MK
Valverde, A
Serrano, M
Guarro, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2524 - 2528
[12] Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the Standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents
Hawser, SP
Norris, H
Jessup, CJ
Ghannoum, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (05) : 1450 - 1452
[13] Utility of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class of compounds
Hawser, SP
Jessup, C
Vitullo, J
Ghannoum, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) : 2738 - 2741
[14] In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum
Li, RK
Ciblak, MA
Nordoff, N
Pasarell, L
Warnock, DW
McGinnis, MR
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) : 1734 - 1736
[15] MAGHOUB S, 1994, SUDAN MED J, V32, P88
[16] KETOCONAZOLE IN THE TREATMENT OF EUMYCETOMA DUE TO MADURELLA-MYCETOMII
MAHGOUB, ES
GUMAA, SA
[J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1984, 78 (03) : 376 - 379
[17] In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
McGinnis, MR
Pasarell, L
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (08) : 2353 - 2355
[18] Mycetoma
McGinnis, MR
[J]. DERMATOLOGIC CLINICS, 1996, 14 (01) : 97 - &
[19] Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species
Meletiadis, J
Mouton, JW
Meis, JFG
Bouman, BA
Donnelly, PJ
Verweij, PE
Network, E
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (12) : 4256 - 4263
[20] National Committee for Clinical Laboratory Standards, 2002, M38A NAT COMM CLIN L

← 1 2 3 →